Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) as 1L Therapy for Hepatocellular Carcinoma

 Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) as 1L Therapy for Hepatocellular Carcinoma

Innovent Reports sNDA Acceptance of Tyvyt (sintilimab) + Byvasda (biosimilar, bevacizumab) as 1L Therapy for Hepatocellular Carcinoma

Shots:

  • The acceptance of sNDA is based on P-III ORIENT-32 study assessing in sintilimab + bevacizumab vs sorafenib in 571 subjects in a ratio (2:1) as 1L treatment for patients with advanced HCC
  • The study met the pre-defined efficacy criteria which showed significant improvement in OS and PFS as assessed by IRRC
  • This marks the fifth NDA application of Tyvyt that has been accepted for review by NMPA. Meanwhile, the application also seeks the fourth indication for Byvasda

Click here ­to­ read full press release/ article | Ref: Innovent Bio | Image: Innovent

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post